Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 16/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.60 |
| ▸ | ADRB3 | P13945 | 6/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | DRD3 | P35462 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | PGR | P06401 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966484 | 1.00 | ADRB2 (0.60) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL2056236 | 1.00 | ADRB2 (0.60) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL2056233 | 1.00 | ADRB2 (0.60) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL13090621 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL3054324 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL3054325 | 0.91 | ADRB2 (0.59) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL2054514 | 0.86 | ADRB2 (0.50) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL11818484 | 0.86 | ADRB2 (0.67) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL965548 | 0.85 | ADRB3 (0.62) | ADRB2ADRB3 | |
| SCHEMBL2056232 | 0.85 | ADRB2 (0.65) | ADRB2ADRB1ADRB3CYP2D6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035004-B1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES INC (US) | 2012-08-08 | — | — | EP | disclosed |
| US-8163758-B2 | Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity | PARION SCIENCES, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008268-A1 | PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY | CACNA1C, CACNA1B, CACNA1G | ADRB2 40/4885ADRB1 42/4885ADRB3 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.